Skip to main content

Development of new multi-valent vaccine systems against Candida pathogens

Project description

A new vaccine against fungal pathogens

Treatment of fungal infections poses a significant medical challenge due to the few available drugs and the associated resistance. Efforts so far to develop vaccines have been met with limited success. VacCan is an EU-funded project that aims to develop a novel vaccine against Candida albicans, the leading cause of fungal infections in humans. Vaccine design will combine three proteins of the fungus, thereby providing multiple antigens against which a more robust immune response can be generated. The VacCan approach will advance vaccine research and pave the way for more effective management of fungal pathogens.


Net EU contribution
€ 212 933,76
WC2R 2LS London
United Kingdom

See on map

London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Other funding
€ 212 933,76